GlassScriptPhysician profile
Marshall G Tanner
NPI 1326031865
$2,541.32
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $685 · 2021: $573 · 2022: $385 · 2023: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.55 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.55 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $456.25 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $309.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $306.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $252.23 | 2019-2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $228.56 | 2019-2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.52 | 2019-2023 | Jardiance, Tradjenta |
| Novo Nordisk INC | $124.45 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.43 | 2019-2022 | |
| Pfizer INC. | $85.42 | 2020-2021 | |
| Abbvie INC. | $60.07 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $56.42 | 2019 | |
| Allergan, INC. | $54.36 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.37 | 2019 | |
| Xeris Pharmaceuticals, INC. | $45.11 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $43.59 | 2023 | Aptiom, Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $30.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.82 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.52 | 2022 | |
| Merck Sharp & Dohme LLC | $20.93 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.54 | 2020 | |
| Antares Pharma, INC. | $15.31 | 2020 | |
| Eisai INC. | $14.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2020 | |
| Medtronic, INC. | $13.94 | 2022 | |
| Lilly USA, LLC | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.